Volition America

Volition America is the U.S. subsidiary of VolitionRx Limited, a multi-national epigenetics and diagnostics company focused on blood-based tests built on nucleosome quantification. The company develops and helps commercialize the Nu.Q suite of assays, which are designed for early disease detection and disease monitoring in both human and veterinary settings. Its core technology, Nucleosomics, measures circulating nucleosomes and related biomarkers such as NETosis-associated markers, with applications in cancer, sepsis, thrombosis-related conditions, and translational drug-development services. Volition America has supported U.S. clinical studies, FDA-oriented development work, and innovation activities from its California operation. The broader Volition group already commercializes the Nu.Q Vet Cancer Test and is advancing human applications including Nu.Q NETs and partner-enabled assay development.